$70.61 meals Payment -- Allergan (AbbVie) to Dr. Patricia Davis
Plastic Surgeon Receives $70.61 Meal from Allergan for Eylea-Related Discussion
This page provides a detailed analysis of a $70.61 meals payment from Allergan (AbbVie) to Dr. Patricia Davis. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $70.61 |
| Payment Type | meals |
| Payment Nature | Food and Beverage |
| Pharmaceutical Company | Allergan (AbbVie) |
| Physician | Dr. Patricia Davis |
| NPI Number | 1754061894 |
| Physician Specialty | Plastic Surgery |
| Location | Tampa, FL |
| Date of Payment | 2026-02-21 |
| Related Drug/Device | Eylea |
| Conflict Assessment | Low -- Routine |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Allergan (AbbVie) made a $70.61 meals payment to Patricia Davis, a Plastic Surgery specialist in Tampa, FL. The payment was associated with Eylea. Patricia Davis received a meal valued at $70.61 from Allergan (AbbVie) on February 21, 2026. The payment was for Food and Beverage, specifically related to the drug Eylea. This payment occurred in Tampa, Florida.
Patient Guidance: What This Payment Means for You
This payment represents a meal provided by a pharmaceutical company, which may be related to discussions about their products. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Meals provided by pharmaceutical companies to physicians are common across many specialties, including Plastic Surgery, and are generally considered a minor form of compensation.
Regulatory Context: Sunshine Act Requirements
Payments to physicians by pharmaceutical companies are subject to disclosure under the Open Payments program to ensure transparency in the healthcare industry.
Related Topics
This payment is related to the following healthcare transparency topics:
- meals
- food-and-beverage
- allergan
- abbvie
- patricia-davis
- eylea
- plastic-surgery
Understanding meals Payments
Food and beverage payments cover meals provided to physicians during pharmaceutical sales representative visits, medical conferences, and educational events. While individual meal payments tend to be small (often under $100), research published in JAMA Internal Medicine has shown that even modest meals can be associated with changes in prescribing behavior. Meal payments are the most common type of pharmaceutical payment to physicians.
Frequently Asked Questions About This Payment
What was this $70.61 payment for?
This was a meals payment of $70.61 from Allergan (AbbVie) to Patricia Davis, categorized as "Food and Beverage". It was associated with Eylea. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Patricia Davis accept pharmaceutical money?
Yes, Patricia Davis received this $70.61 payment from Allergan (AbbVie). Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Patricia Davis's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this meals payment?
A meals payment of $70.61 is generally routine and common in the industry. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Plastic Surgery?
To compare this payment against Plastic Surgery averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Plastic Surgery physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Patricia Davis's relationship with Allergan (AbbVie)?
The payment amount is relatively small, suggesting a routine interaction. This $70.61 meals payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Plastic Surgery?
The payment type is 'meals', a common form of 'speaking fees' or 'consulting fees' in the industry.
What should patients do after learning about this payment?
This payment represents a meal provided by a pharmaceutical company, which may be related to discussions about their products.
What else should I know about this meals payment?
The date of payment is in the future (2026), which may indicate a scheduled event or a data entry lag.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.